IL17A and autoimmune disease: In addition, recent clinical successes of Otezla (Apremilast) and VTP-43742 (Vitae Pharmaceuticals) in psoriasis, psoriatic arthritis, autoimmune uveitis and/or ankylosing spondylitis through reduction in circulating IL-17A levels [10, 11] support that targeting RORγt is a viable and potentially high value therapeutic strategy for IL-17-driven autoimmune disorders.